R R

What Is Sernivo?

Sernivo is a prescription topical corticosteroid medication containing betamethasone dipropionate 0.05% in a spray formulation. It is approved for treatment of mild to moderate plaque psoriasis in adults aged 18 years and older. Plaque psoriasis causes thickened, inflamed skin patches that can develop scales, itching, and discomfort. Sernivo is applied directly to affected skin areas twice daily for a limited treatment period. It reduces inflammatory activity associated with psoriasis but does not cure the underlying immune-mediated disease. Sernivo must not be used in the eyes, mouth, or vagina and should be kept away from sensitive skin areas identified in the prescribing instructions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Sernivo?

Sernivo is a prescription topical corticosteroid medication containing betamethasone dipropionate 0.05% in a spray formulation. It is approved for treatment of mild to moderate plaque psoriasis in adults aged 18 years and older. Plaque psoriasis causes thickened, inflamed skin patches that can develop scales, itching, and discomfort. Sernivo is applied directly to affected skin areas twice daily for a limited treatment period. It reduces inflammatory activity associated with psoriasis but does not cure the underlying immune-mediated disease. Sernivo must not be used in the eyes, mouth, or vagina and should be kept away from sensitive skin areas identified in the prescribing instructions.

read more about sernivo ...

Copy this HTML:

Copy HTML Copied!

How Does Sernivo Work?

Sernivo contains betamethasone dipropionate, a corticosteroid that acts on glucocorticoid receptors in skin cells. This changes the production and activity of substances involved in inflammation, reducing redness, swelling, and itching in affected areas. Corticosteroids also influence local immune responses and blood vessel activity. In plaque psoriasis, these effects can reduce the thickness and irritation of inflamed skin patches. Sernivo is intended for local treatment, although some medication can be absorbed through the skin, particularly when applied to large areas or under coverings. Excessive exposure can suppress normal adrenal hormone production and cause other corticosteroid-related effects.

What Skin Condition Does Sernivo Treat?

Sernivo is approved for mild to moderate plaque psoriasis in adults aged 18 years and older. Plaque psoriasis is a chronic inflammatory condition that produces raised, scaly patches, commonly affecting the elbows, knees, trunk, and other skin surfaces. Sernivo can reduce inflammation in eligible areas during short treatment courses. It is not approved for pediatric patients or for every type of psoriasis. The label advises avoiding the face, scalp, underarms, groin, and other skin folds, where corticosteroid-related skin complications can be more likely. Patients with skin thinning at the planned treatment site should not apply Sernivo there. A clinician determines when another psoriasis treatment is more appropriate.

How Should Sernivo Be Applied?

Shake the Sernivo spray bottle before use. Apply the medication to affected skin areas twice daily and rub it in gently. Treatment should continue only until the condition is controlled, for a maximum of four weeks. Use beyond four weeks is not recommended. Do not apply Sernivo to areas of skin thinning or use it on the face, scalp, underarms, groin, or skin folds. Avoid covering treated areas with airtight dressings unless a healthcare professional directs it. Sernivo is for external skin use only and must not be sprayed into the eyes or onto mucous membranes. Wash hands after application unless the hands themselves are being treated.

What Are the Side Effects and Warnings of Sernivo?

Possible adverse effects include burning, stinging, itching, irritation, dryness, and skin discomfort at application sites. Prolonged or excessive topical corticosteroid use can cause skin thinning, stretch marks, changes in pigmentation, and increased absorption into the bloodstream. Systemic absorption may suppress the hypothalamic-pituitary-adrenal axis and affect normal cortisol production. Applying corticosteroids to large areas or under occlusive dressings increases these risks. Sernivo should not be applied near or inside the eyes because corticosteroid exposure can cause ocular complications. Patients should report worsening irritation, signs of skin infection, pronounced skin thinning, or unexpected systemic symptoms. Treatment must not extend beyond four weeks without reassessment.

Common Questions About Sernivo

Is Sernivo the same as betamethasone?

Yes. Sernivo contains betamethasone dipropionate 0.05% in a topical spray intended for plaque psoriasis.

Can Sernivo treat plaque psoriasis?

Yes. Sernivo is approved for mild to moderate plaque psoriasis in adults aged 18 years and older.

How long can Sernivo be used?

Sernivo is applied twice daily for up to four weeks and should be stopped earlier when adequate control is achieved.

Can Sernivo be sprayed on the face or near the eyes?

No. Sernivo should not be applied to the face or used in or near the eyes. It is intended for specified skin treatment areas only.

References

Betamethasone Dipropionate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/21800. Date Accessed November 6, 2026.

Betamethasone Topical. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682799.html. Date Accessed November 6, 2026.

DailyMed - SERNIVO (betamethasone dipropionate) spray. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b3d1b0-da9b-11eb-ad76-0800200c9a66. Date Accessed November 6, 2026.

SERNIVO Instructions for Use. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1b3d1b0-da9b-11eb-ad76-0800200c9a66. Date Accessed November 6, 2026.

SERNIVO Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b3d1b0-da9b-11eb-ad76-0800200c9a66. Date Accessed November 6, 2026.